Suppr超能文献

非小细胞肺癌患者 TG/HDL-C 和非 HDL-C/HDL-C 比值的预后意义:一项回顾性研究。

Prognostic significance of TG/HDL-C and non-HDL-C/HDL-C ratios in patients with non-small cell lung cancer: a retrospective study.

机构信息

Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, China.

Graduate School, Hebei Medical University, Shijiazhuang, China.

出版信息

J Int Med Res. 2022 Aug;50(8):3000605221117211. doi: 10.1177/03000605221117211.

Abstract

OBJECTIVE

Lung cancer is a malignancy with high a mortality rate that threatens human health. This study is aimed to explore the correlation among the triglyceride/high-density lipoprotein ratio (TG/HDL-C), non-high-density lipoprotein/high-density lipoprotein ratio (non-HDL-C/HDL-C) and survival of patients with non-small cell lung cancer (NSCLC) undergoing video-associated thoracic surgery (VATS).

METHODS

This retrospective study analyzed 284 patients with NSCLC who underwent VATS at Hebei General Hospital, Shijiazhuang, China. The time-dependent receiver operating characteristic curve was used to determine the optimal cutoff value and evaluate the area under the curve. Kaplan-Meier and Cox regression analyses were performed to determine the prognostic effect.

RESULTS

The median overall survival (OS) was 46 months. Patients with low TG/HDL-C and low non-HDL-C/HDL-C had a longer OS. The low non-HDL-C/HDL-C group showed a longer mean survival time (59.00 vs. 52.35 months). Multivariate analysis revealed that TG/HDL-C and non-HDL-C/HDL-C were significantly correlated with OS.

CONCLUSIONS

TG/HDL-C and non-HDL-C/HDL-C are associated with the prognosis of patients with NSCLC who received VATS. Preoperative serum TG/HDL-C and non-HDL-C/HDL-C may be effective independent prognostic factors for predicting the outcomes of patients with NSCLC.

摘要

目的

肺癌是一种死亡率高的恶性肿瘤,威胁着人类的健康。本研究旨在探讨视频辅助胸腔镜手术(VATS)治疗非小细胞肺癌(NSCLC)患者中甘油三酯/高密度脂蛋白比值(TG/HDL-C)、非高密度脂蛋白/高密度脂蛋白比值(non-HDL-C/HDL-C)与生存的相关性。

方法

本回顾性研究分析了在中国河北医科大学第一医院接受 VATS 治疗的 284 例 NSCLC 患者。采用时间依赖性受试者工作特征曲线确定最佳截断值和评估曲线下面积。采用 Kaplan-Meier 和 Cox 回归分析确定预后效果。

结果

中位总生存期(OS)为 46 个月。TG/HDL-C 和 non-HDL-C/HDL-C 低的患者 OS 更长。non-HDL-C/HDL-C 低的组中位生存时间更长(59.00 与 52.35 个月)。多变量分析显示,TG/HDL-C 和 non-HDL-C/HDL-C 与 OS 显著相关。

结论

TG/HDL-C 和 non-HDL-C/HDL-C 与接受 VATS 治疗的 NSCLC 患者的预后相关。术前血清 TG/HDL-C 和 non-HDL-C/HDL-C 可能是预测 NSCLC 患者预后的有效独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367c/9373166/81f191f2b0fa/10.1177_03000605221117211-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验